Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 8

1.

FGFR3 mutations in prostate cancer: association with low-grade tumors.

Hernández S, de Muga S, Agell L, Juanpere N, Esgueva R, Lorente JA, Mojal S, Serrano S, Lloreta J.

Mod Pathol. 2009 Jun;22(6):848-56. doi: 10.1038/modpathol.2009.46.

2.

Oncogenic role of fibroblast growth factor receptor 3 in tumorigenesis of urinary bladder cancer.

Pandith AA, Shah ZA, Siddiqi MA.

Urol Oncol. 2013 May;31(4):398-406. doi: 10.1016/j.urolonc.2010.07.014. Review.

PMID:
20822928
3.

Clinical significance of fibroblast growth factor receptor-3 mutations in bladder cancer: a systematic review and meta-analysis.

Liu X, Zhang W, Geng D, He J, Zhao Y, Yu L.

Genet Mol Res. 2014 Feb 20;13(1):1109-20. doi: 10.4238/2014.February.20.12. Review.

4.

Fibroblast growth factor receptor-3 in urothelial tumorigenesis.

Iyer G, Milowsky MI.

Urol Oncol. 2013 Apr;31(3):303-11. doi: 10.1016/j.urolonc.2011.12.001. Review.

PMID:
22285006
5.

FGFR3 mutations and the skin: report of a patient with a FGFR3 gene mutation, acanthosis nigricans, hypochondroplasia and hyperinsulinemia and review of the literature.

Blomberg M, Jeppesen EM, Skovby F, Benfeldt E.

Dermatology. 2010;220(4):297-305. doi: 10.1159/000297575. Review.

PMID:
20453470
6.

Fibroblast growth factor receptor 3 mutations in epidermal nevi and associated low grade bladder tumors.

Hernández S, Toll A, Baselga E, Ribé A, Azua-Romeo J, Pujol RM, Real FX.

J Invest Dermatol. 2007 Jul;127(7):1664-6. Review.

7.
8.

Somatic oncogenic mutations, benign skin lesions and cancer progression: where to look next?

Toll A, Real FX.

Cell Cycle. 2008 Sep 1;7(17):2674-81. Review.

PMID:
18728396
Items per page

Supplemental Content

Support Center